Bicycle Therapeutics plc Long-Lived Assets
Bicycle Therapeutics plc (BCYC) had Long-Lived Assets of $18.67 million as of 2026-06-30, per its 10-Q filed 2026-07-30.
Financial Statements › Notes › Segment Reporting
us-gaap:NoncurrentAssets · last filed 2026-07-30
- 2026-06-30: Long-Lived Assets $18.67M.
- 2026-03-31: Long-Lived Assets $20.27M.
- 2025-12-31: Long-Lived Assets $21.91M.
- 2025-09-30: Long-Lived Assets $11.42M.
| Period end | Long-Lived Assets |
|---|---|
| 2026-06-30 | $18.67M 10-Q · filed 2026-07-30 |
| 2026-03-31 | $20.27M 10-Q · filed 2026-04-30 |
| 2025-12-31 | $21.91M 10-Q · filed 2026-07-30 |
| 2025-09-30 | $11.42M 10-Q · filed 2025-10-30 |
| 2025-06-30 | $14.11M 10-Q · filed 2025-08-08 |
| 2025-03-31 | $15.45M 10-Q · filed 2025-05-01 |
| 2024-12-31 | $17.19M 10-K · filed 2026-03-17 |
| 2024-09-30 | $20.61M 10-Q · filed 2024-10-31 |
| 2024-06-30 | $22.52M 10-Q · filed 2024-08-06 |
| 2024-03-31 | $24.81M 10-Q · filed 2024-05-02 |
| 2023-12-31 | $27.68M 10-K · filed 2025-02-25 |
| 2023-09-30 | $30.20M 10-Q · filed 2023-11-02 |
| 2023-06-30 | $33.59M 10-Q · filed 2023-08-03 |
| 2023-03-31 | $36.98M 10-Q · filed 2023-05-04 |
| 2022-12-31 | $32.77M 10-K · filed 2024-02-20 |
| 2022-09-30 | $29.70M 10-Q · filed 2022-11-03 |
| 2022-06-30 | $31.89M 10-Q · filed 2022-08-04 |
| 2022-03-31 | $25.60M 10-Q · filed 2022-05-05 |
| 2021-12-31 | $17.79M 10-K · filed 2023-02-28 |
| 2021-09-30 | $5.68M 10-Q · filed 2021-11-04 |
| 2021-06-30 | $5.88M 10-Q · filed 2021-08-05 |
| 2021-03-31 | $6.27M 10-Q · filed 2021-05-06 |
| 2020-12-31 | $3.61M 10-K · filed 2022-03-01 |
| 2020-09-30 | $3.50M 10-Q · filed 2020-11-05 |
| 2020-06-30 | $3.80M 10-Q · filed 2020-08-05 |
| 2020-03-31 | $4.02M 10-Q · filed 2020-05-07 |
| 2019-12-31 | $4.35M 10-K · filed 2021-03-11 |
| 2019-09-30 | $4.33M 10-Q · filed 2019-11-07 |
| 2019-06-30 | $4.39M 10-Q · filed 2019-08-08 |
| 2018-12-31 | $1.82M 10-K · filed 2020-03-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Quantum Cyber N.V. (QUCY) | $0.113B | ||
| Immuneering Corp (IMRX) | United States | $0.113B | -12.51 |
| GENELUX Corp (GNLX) | United States | $0.110B | -3.83 |
| Equillium, Inc. (EQ) | United States | $0.109B | -11.27 |
| Biomea Fusion, Inc. (BMEA) | United States | $0.107B | -3.30 |
| Polaryx Therapeutics, Inc. (PLYX) | United States | $0.106B | |
| OnKure Therapeutics, Inc. (OKUR) | United States | $0.119B | -3.13 |
| Coya Therapeutics, Inc. (COYA) | United States | $0.121B | -6.35 |
| CUMBERLAND PHARMACEUTICALS INC (CPIX) | United States | $0.121B | -8.95 |
| ProMIS Neurosciences Inc. (PMN) | $0.102B |